Prolia (Denosumab) Medicare Part D Coverage

How Medicare Part D Classifies Prolia

Most Medicare Part D plans place Prolia on Tier 4 (preferred specialty) or Tier 5 (non-preferred specialty), meaning coinsurance rather than a flat copay applies. The Centers for Medicare & Medicaid Services (CMS) require Part D plans to cover medically necessary osteoporosis treatments, and denosumab appears on the majority of national formularies 1. Tier placement varies by plan sponsor; UnitedHealthcare AARP plans and Humana Walmart plans have historically listed Prolia at Tier 5 with 25-33% coinsurance 2.

Your actual cost depends on which cost-sharing phase you occupy. In the initial coverage phase (after meeting the deductible), expect 25-33% coinsurance on a specialty tier. For a $1,500 injection, that translates to $375-$495 per dose 3. Once you reach the coverage gap, the manufacturer discount and plan contributions reduce your share. Under the Inflation Reduction Act provisions fully implemented in 2025, total annual out-of-pocket spending is capped at $2,000 regardless of drug costs 4.

This cap means that even without additional assistance, a beneficiary taking Prolia twice yearly will never pay more than $2,000 combined across all Part D medications in a calendar year.

Part B vs. Part D: Which Covers Your Prolia Injection?

The coverage pathway depends on where and how Prolia is administered. Medicare Part B covers Prolia when a physician or qualified healthcare provider administers the injection in an office, hospital outpatient department, or clinic setting 5. Under Part B, the standard 20% coinsurance applies after the Part B deductible ($257 in 2026), making the per-injection cost roughly $300 for most beneficiaries with no supplemental coverage.

Medicare Part D applies when Prolia is dispensed through a specialty pharmacy for self-administration or home health administration. The distinction matters financially: Part B beneficiaries with a Medigap Plan G or similar supplement may owe nothing beyond premiums. Part D beneficiaries face variable coinsurance until hitting the $2,000 cap 6.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend denosumab as first-line therapy for high-fracture-risk postmenopausal women, making coverage disputes relatively uncommon for appropriate candidates 7. Prior authorization requirements exist in some Part D plans but rarely result in denial when bone mineral density T-scores meet threshold criteria (T-score ≤ -2.5 or fragility fracture history).

What You Will Actually Pay in 2026

A concrete cost breakdown for a standard Part D plan with Prolia at Tier 5 (33% coinsurance):

First injection (January): After a $590 deductible (2026 standard), your coinsurance on the remaining cost applies. If the plan's negotiated price is $1,400, you pay roughly $462. This single injection likely pushes you past the initial coverage limit 8.

Second injection (July): By mid-year, most Prolia users have already reached the $2,000 annual cap. You pay $0 for the second injection. The Medicare Prescription Payment Plan also allows spreading costs across monthly installments rather than paying large lump sums at the pharmacy 9.

For beneficiaries taking other specialty medications (e.g., for diabetes or cardiovascular disease), the $2,000 cap provides even faster relief. Your Prolia costs count toward the same annual maximum as every other Part D drug.

Amgen's Patient Assistance Programs

Amgen operates two primary programs that reduce Prolia costs for Medicare beneficiaries and uninsured patients 10.

Amgen Safety Net Foundation: This program provides Prolia at no cost to patients with household incomes at or below 300% of the Federal Poverty Level ($46,060 for a single individual in 2026). Medicare beneficiaries qualify if they lack Part D coverage or fall into a coverage gap scenario. Application requires income documentation and a prescriber signature 11.

Amgen FIRST STEP Program: Commercial insurance patients (not Medicare-eligible) can reduce copays to as little as $5 per injection. This program explicitly excludes Medicare, Medicaid, and Tricare beneficiaries per federal anti-kickback statute requirements 12.

Dr. Ethel Siris, professor emerita of medicine at Columbia University, has noted: "The financial burden of osteoporosis therapy remains a significant barrier to adherence, particularly for injectable agents like denosumab where out-of-pocket costs can reach several hundred dollars per dose even with insurance."

For Medicare beneficiaries specifically, the combination of the $2,000 annual cap and the Medicare Prescription Payment Plan represents the most impactful cost reduction since 2020.

Biosimilar Denosumab: Timeline and Savings Potential

The FDA approved the first denosumab biosimilar (denosumab-bddz, marketed as Wyost by Sandoz) in 2024, with market launch occurring in stages through 2025-2026 13. Additional biosimilar applications from Fresenius Kabi and Samsung Bioepis are under FDA review.

Biosimilar pricing for monoclonal antibodies typically runs 15-35% below the reference product. For Prolia, this suggests a biosimilar price of $975-$1,275 per injection 14. Medicare Part D plans have financial incentives to prefer biosimilars on formulary, potentially placing them at lower tiers than branded Prolia.

The FREEDOM trial (N=7,868) established denosumab's efficacy with a 68% reduction in vertebral fractures, 40% reduction in hip fractures, and 20% reduction in nonvertebral fractures over 36 months versus placebo 15. Biosimilars must demonstrate equivalent efficacy and safety to this established profile. The Endocrine Society's 2024 position statement supports biosimilar substitution when clinically appropriate and cost-effective 16.

How to Get Prolia Cheap: Step-by-Step Strategy

Reducing your Prolia costs requires a systematic approach that stacks multiple programs.

Step 1: Confirm your coverage pathway. Call your Part D plan to verify Prolia's tier and whether Part B billing is available through your provider's office. Part B with a Medigap supplement is often the lowest-cost route 17.

Step 2: Request prior authorization early. If your plan requires PA, have your prescriber submit bone density results and fracture risk assessment (FRAX score) at least 2 weeks before your scheduled injection. The WHO FRAX tool calculates 10-year fracture probability and supports medical necessity documentation 18.

Step 3: Enroll in the Medicare Prescription Payment Plan. This allows you to spread your out-of-pocket costs across monthly payments rather than facing a large bill at the pharmacy window. Contact your Part D plan directly to enroll 19.

Step 4: Apply for Amgen Safety Net if income-eligible. Even Medicare beneficiaries can qualify if their income falls below 300% FPL. The application is available at amgensafetynet.com or by calling 1-888-762-6436 20.

Step 5: Ask about biosimilar availability. If a denosumab biosimilar is on your plan's formulary at a lower tier, switching could reduce your coinsurance percentage. Discuss with your prescriber whether this is appropriate for your situation.

Step 6: Consider Extra Help (Low-Income Subsidy). Medicare beneficiaries with limited income and resources may qualify for Extra Help, which reduces Part D premiums, deductibles, and copays. Income limits for full Extra Help in 2026 are approximately $22,590 for individuals 21.

Insurance Coverage Beyond Medicare

For patients under 65 with commercial insurance, denosumab coverage patterns differ substantially from Medicare.

Most commercial plans cover Prolia under the medical benefit (like Part B) when administered in a provider's office. The National Osteoporosis Foundation reports that 89% of commercial plans cover denosumab without step therapy requirements for patients meeting bone density criteria 22. Copays under commercial medical benefits typically range from $50-$150 per injection after specialist visit copays.

Employer-sponsored plans with pharmacy benefits may route Prolia through specialty pharmacy channels. In these cases, specialty copay maximums (often $150-$250 per fill) apply. Amgen's FIRST STEP copay card can reduce commercial copays to $5 for eligible patients 23.

Medicaid coverage varies by state but is generally available without prior authorization for patients meeting AACE or Endocrine Society guideline criteria. The Medicaid Drug Rebate Program ensures net costs remain low for state programs 24.

Clinical Considerations Affecting Coverage Decisions

Plan formulary committees evaluate denosumab's place in therapy relative to oral bisphosphonates (alendronate, risedronate), which cost $15-$50/month generic. Most plans require documentation that oral bisphosphonates are contraindicated, not tolerated, or have failed before approving denosumab 25.

Valid reasons for bisphosphonate failure or intolerance include: esophageal stricture or motility disorders, inability to remain upright for 30 minutes, GI adverse effects despite proper administration, creatinine clearance <35 mL/min (contraindication for bisphosphonates but not denosumab), and continued bone loss on oral therapy documented by DXA 26.

The DAPS trial demonstrated that patients switching from alendronate to denosumab gained an additional 1.9% lumbar spine BMD over 12 months compared to continuing alendronate 27. This data supports coverage for switch patients and strengthens prior authorization appeals.

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, has stated: "Denosumab fills a clear clinical niche for patients who cannot take oral bisphosphonates and for those requiring more potent antiresorptive therapy based on fracture risk severity."

Appealing a Medicare Part D Denial

If your Part D plan denies coverage, you have structured appeal rights under CMS regulations 28.

Level 1: Coverage Determination Redetermination. Submit within 60 days of denial. Include DXA results, FRAX score, documentation of bisphosphonate intolerance, and a letter of medical necessity from your prescriber. Plans must respond within 7 days (72 hours for expedited requests).

Level 2: Independent Review Entity (IRE). If Level 1 fails, the case goes to an external reviewer. The IRE overturns approximately 40% of pharmacy coverage denials according to CMS data 29.

Level 3 and beyond: Administrative Law Judge hearing (for amounts over $190 in 2026), Medicare Appeals Council, and federal district court. Most Prolia denials resolve at Level 1 or 2 when documentation is complete.

Discontinuation Risks and Coverage Continuity

One coverage factor unique to denosumab: abrupt discontinuation triggers rapid bone loss. BMD decreases 5-7% within 12 months of stopping, with vertebral fracture risk increasing above pre-treatment baseline 30. The FREEDOM extension trial documented multiple vertebral fractures in some patients who discontinued after long-term use 31.

This rebound phenomenon means coverage gaps are clinically dangerous. If switching plans during Medicare Open Enrollment (October 15 - December 7), verify the new plan's Prolia coverage before finalizing enrollment. CMS considers continuity of care in coverage transition protections, requiring new plans to provide a temporary supply during the first 90 days of enrollment 32.

If forced to discontinue, the Endocrine Society recommends transitioning to an oral or IV bisphosphonate to prevent rebound bone loss 33. Ensure your prescriber documents this plan in case of coverage interruption.

2026 Policy Changes Affecting Prolia Access

The Inflation Reduction Act's full implementation brings three changes relevant to Prolia access in 2026 34:

1. The $2,000 annual out-of-pocket cap eliminates catastrophic-phase cost exposure
2. Medicare can negotiate prices for select Part D drugs (denosumab is not in the first negotiation cohort but may be selected in future cycles)
3. Part D plans must offer the Medicare Prescription Payment Plan option for installment payments

CMS also finalized rules requiring Part D plans to apply manufacturer rebates at the point of sale in 2026, reducing the sticker price beneficiaries see at the pharmacy 35.